Clinical Trials Logo

Clinical Trial Summary

This Phase Ia study aims to establish the maximum tolerated dose of once-weekly IV infused PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition, the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02042781
Study type Interventional
Source Zucero Pty Ltd
Contact
Status Completed
Phase Phase 1
Start date January 2014
Completion date September 2016

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05514132 - A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid Tumours Phase 1
Terminated NCT04949425 - A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours Phase 1
Not yet recruiting NCT05537051 - A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours Phase 1
Completed NCT02579226 - A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT01668550 - A Phase I Study of AZD0424 Alone and in Combination in Advanced Solid Tumours Phase 1
Completed NCT01058538 - A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02588105 - Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer Phase 1
Recruiting NCT03852823 - Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced Tumours Phase 1
Not yet recruiting NCT06380816 - A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer Phase 1/Phase 2
Completed NCT01585701 - Phase I Study of AT13148, a Novel AGC Kinase Inhibitor Phase 1
Completed NCT03101839 - Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours Phase 1
Completed NCT03150368 - Extended Use of ModraDoc006/r Phase 1
Active, not recruiting NCT02389842 - PIPA: Combination of PI3 Kinase Inhibitors and PAlbociclib Phase 1
Terminated NCT01581060 - Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours Phase 1/Phase 2
Terminated NCT04959266 - A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib Phase 1
Completed NCT04462952 - Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours Phase 1
Active, not recruiting NCT03518606 - Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours Phase 1/Phase 2
Completed NCT02430311 - The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. Phase 1
Terminated NCT01859351 - Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours Phase 1
Completed NCT01163903 - Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours Phase 1